Abstract
The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT1 and MT2 receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype selective MT1 and MT2 ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT3 binding site are included.
Keywords: Melatonin, melatonin receptor agonists, melatonin receptor antagonists, melatonin receptor partial agonists, MT1 receptors, MT2 receptors, MT3 binding site, selective ligands, insomnia, sleep disorders
Current Medicinal Chemistry
Title:Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors
Volume: 19 Issue: 21
Author(s): D. P. Zlotos
Affiliation:
Keywords: Melatonin, melatonin receptor agonists, melatonin receptor antagonists, melatonin receptor partial agonists, MT1 receptors, MT2 receptors, MT3 binding site, selective ligands, insomnia, sleep disorders
Abstract: The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT1 and MT2 receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype selective MT1 and MT2 ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT3 binding site are included.
Export Options
About this article
Cite this article as:
P. Zlotos D., Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors, Current Medicinal Chemistry 2012; 19 (21) . https://dx.doi.org/10.2174/092986712801323153
DOI https://dx.doi.org/10.2174/092986712801323153 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Combination of 3D-QSAR Modeling and Molecular Docking Approach for the Discovery of Potential HIF Prolyl Hydroxylase Inhibitors
Medicinal Chemistry Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Adenosine in the Inflamed Gut: A Janus Faced Compound
Current Medicinal Chemistry Microfluidic Devices for Cell, Tissue and Embryo Culture
Recent Patents on Regenerative Medicine Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents
Current Medicinal Chemistry Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Structural Modeling and Identification of Imperatorin as Novel L-type Calcium Channel Blocker
Medicinal Chemistry Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Tissue Engineered Bone Grafts: Biological Requirements, Tissue Culture and Clinical Relevance
Current Stem Cell Research & Therapy Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry